OXB.L vs PGEN
OXB.L: A leader in the viral vector manufacturing sector, providing essential development and production services for advanced cell and gene therapy treatments. PGEN: Gene therapy precision medicine company with FDA-approved adenoviral immunotherapy for HPV-driven respiratory disease and a development pipeline of CAR-T and viral vector candidates across oncology and infectious disease.
Side-by-side fundamentals
| Metric | OXB.L | PGEN | Edge |
|---|---|---|---|
| Price as of 2026-08-03 close | £5.61 | $6.89 | |
| Market cap as of 2026-08-06 | n/a | $2.5B | |
| PEG as of 2026-08-06 | n/a | -0.05 | |
| Net margin as of 2026-08-06 | n/a | -647.0% | |
| Gross margin as of 2026-08-06 | n/a | +80.1% | |
| Operating margin as of 2026-08-06 | n/a | -297.2% | |
| ROE as of 2026-08-06 | n/a | -642.5% | |
| ROA as of 2026-08-06 | n/a | -144.1% | |
| Debt / equity as of 2026-08-06 | n/a | 4.62 | |
| Revenue growth (YoY) as of 2026-08-06 | n/a | +652.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -28.9% | |
| Beta as of 2026-08-06 | n/a | 0.98 | |
| 1-year return as of 2026-08-03 close | +20.8% | +257.0% | PGEN higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-03.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.